Summary
The antiarrhythmic properties of amiodarone at the ventricular level were discovered in the early 1970s. The unanimously recognised efficacy of amiodarone includes a weak negative inotropic effect and compensatory vasodilatory properties, making amiodarone particularly suitable for treating the potentially malignant arrhythmias associated with organic disease. In a review of 611 hospitalised patients on amiodarone, and 353 patients in whom the drug had been prescribed, over a 52-month period in our 60-bed department, we noted that amiodarone was prescribed in 53% of patients for arrhythmias and in 47% of patients for coronary insufficiency. Ventricular arrhythmias represented 13% of the rhythmic indications. These indications differ from those in the USA. The efficacy (70 to 90%) of amiodarone in ventricular extrasystoles has been shown in open studies. In coronary patients, the antiarrhythmic activity of amiodarone is superior to that of propranolol. However, there has been no controlled study because the need for a loading dosage, and the electrocardiographic effects render such studies difficult. After myocardial infarction, ventricular arrhythmias constitute a significant risk factor independently of prognosis; amiodarone may be useful in this indication, and studies of the European Myocardial Infarction Amiodarone Trial (EMIAT) type will examine its value here. Since 1973, it has been recognised that amiodarone can prevent ventricular tachycardia in 55 to 89% of patients in the clinical situation. After a long-standing controversy, the positive predictive value of programmed stimulation has finally been agreed on. In hypertrophic cardiomyopathy, retrospective studies suggest a reduction in mortality in patients treated with amiodarone. By contrast, the value of amiodarone in dilated cardiomyopathy requires more intensive investigation. We consider amiodarone to be indicated in ventricular arrhythmic complexes, particularly if they are associated with an ejection fraction of less than 35% and/or atrial fibrillation. The value of amiodarone in arrhythmias associated with heart failure needs to be evaluated. In conclusion, amiodarone is a powerful antiarrhythmic agent but, because of the possibility of dose- and duration-dependent side effects, evaluation of the risk: benefit ratio in each indication is needed.
Similar content being viewed by others
References
Beckers J, Kulbertus HE. Class III drugs: amiodarone. European Heart Journal 8 (Suppl. A): 53–59, 1987
Burkart F, Pfisterer M, Kiowski W, Burckhardt D, Follath F. Improved survival of patients with asymptomatic ventricular arrhythmias after myocardial infarction with amiodarone. Circulation 80: 11–119, 1989
Cardiac Arrhythmia Suppression Trial (CAST). Increased mortality due to encainide and flecainide in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 321: 406–412, 1989
Charlier R, Deltour G. Correction des arythmies expérimentales par l’amiodarone. Journal de Pharmacologie 1: 175, 1970
Ezri MD, Shima MA, Denes P. Amiodarone. A review of its clinical and electrophysiological effects. Clinical Progress in Pacing and Clinical Electrophysiology 1: 20, 1983
Fauchier JP, Brochier M, Raynaud R. Etude clinique des effets anti-arythmiques ventriculaires de l’amiodarone (orale et injectable). Annales de Cardiologie et d’Angéiologie 22: 427–435, 1973
Fogoros RN, Fielder SB, Elson JJ. Empiric amiodarone versus “ineffective” drug therapy in patients with refractory ventricular tachyarrhythmias. Pace — Pacing and Clinical Electrophysiology 11: 1009–1017, 1988
Fournier C, Brunet M, Bah M, et al. Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction. European Heart Journal 10: 1090–1100, 1989
Hamer AWF, Arkles BL, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. Journal of the American College of Cardiology 14: 1768–1774, 1989
Hamer AW, Finerman WB, Peter T, et al. Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. American Heart Journal 102: 992–1000, 1981
Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New England Journal of Medicine 305: 539–545, 1981
Heger JJ, Prystowsky EN, Miles WN, Zipes DP. Clinical use and pharmacology of amiodarone. Medical Clinics of North America 68: 1339–1366, 1984
Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia of ventricular fibrillation. Journal of the American College of Cardiology 13: 442–449, 1989
Horowitz LN, Greenspan AM, Spielman SR, et al. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. American Journal of Cardiology 55: 367–371, 1985
Huang SK, Messer JV, Dewes P. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy: observation in 35 patients. American Journal of Cardiology 51: 507, 1983
Kaski JC, Girotti LA, Messuti H, et al. Long-term management of sustained, recurrent symptomatic ventricular tachycardia with amiodarone. Circulation 64: 273–279, 1981
Lévy S. Combination therapy for cardiac arrhythmias. American Journal of Cardiology 61: 95A-100A, 1988
Manolis AS, Uricchio F, Estes M. Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone. American Journal of Cardiology 63: 1052–1057, 1989
Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory monitoring in patients with hypertrophic cardiomyopathy: a prospective study. American Journal of Cardiology 48: 252, 1981
McKenna W, Adams KM, Poloniecki JD, Dickie S, Oakley CM, et al. Long-term survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Circulation 80: II–7, 1989
McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. American Journal of Cardiology 54: 802–810, 1984
Meinertz T, Hofmann T, Kasper W. Significance of ventricular arrhythmias in dilated cardiomyopathy. American Journal of Cardiology 53: 902, 1984
Metge M, Lévy S, Cointe R, et al. Extrasystole ventriculaire complexe. Archives des Maladies du Coeur et des Vaisseaux 13: 1893–1898, 1987
Morady F, Scheinman MM, Hess DS, et al. Electrophysiologic testing in the management of survivors of out-of-hospital cardiac arrest. American Journal of Cardiology 51: 85–89, 1983
Myers M, Peter T, Weiss D, et al. Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. American Heart Journal 119: 8–14, 1990
Nademanee K, Hendrickson JA, Cannom DS, et al. Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. American Heart Journal 6: 759–768, 1981
Packer M for the Captopril-Digoxin Multicentre Research Group. Asymptomatic ventricular tachycardia identifies patients with heart failure at risk of clinical progression rather than sudden death. Circulation 80: 11–120, 1989
Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. American Journal of Cardiology 38: 934–944, 1976
Tadei A, Richard M, Victor J, Delhumeau M, Geslin PH. Etude de l’amiodarone dans les troubles du rythme ventriculaire. Archives Med. Ouest 6: 415–434, 1974
Vastesaeger MM, Gillot PM. L’effet antiarythmique de l’amiodarone. Bruxelles Medical 51: 99, 1971
Ward DE, Camm AJ, Spurrell RAJ. Clinical antiarrhythmic effect of amiodarone in patients with resistant paroxysmal tachycardias. British Heart Journal 44: 91–95, 1980
Zehender et al. Sudden death in dilated cardiomyopathy. Conventional versus amiodarone treatment. Journal of the American College of Cardiology 15 (Suppl. A): 33, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levy, S. The Value of Oral Amiodarone in the Treatment of Ventricular Arrhythmias in Heart Disease. Drugs 41 (Suppl 2), 47–53 (1991). https://doi.org/10.2165/00003495-199100412-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199100412-00007